A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes

Inclusion Criteria: * Participants must have type 1 diabetes and have been treated with insulin therapy for at least 1 year * Participants must be using Continuous Glucose Monitoring (CGM) with total CGM use ≥ 2 months in the prior 6 months * Participants must have been on the same type of short acting insulin (Humalog U-100, Novolog, Admelog, or Apidra) for at least 30 days prior to screening * Participants must have been treated with long-acting insulin degludec U-100 for at least 30 days prior to screening Exclusion Criteria: * Participants must not have had more than 1 emergency room visit or hospitalization due to poor glucose control within 6 months before screening * Participants must not have had more than 1 episode of severe hypoglycemia within the last 90 days prior to screening * Participants must not be taking certain diabetes medications that are not allowed for study participation